Evidence map›Paper›PMID 34931497›Full record

ArticleJournal of Korean medical science2021

Vimentin Targeted Nano-gene Carrier for Treatment of Renal Diseases.

Ansuja Pulickal Mathew, Saji Uthaman, Eun Hui Bae, Jae Young Lee, In-Kyu Park

Open access · goldAbstract read
In one paragraph

Article in Journal of Korean medical science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Nanotherapeutics in Kidney Disease: Innovations, Challenges, and Future Directions.Journal of the American Society of Nephrology : JASN · 2025
    Review
  5. Review
  6. Gene therapy and kidney diseases.Molecular therapy. Methods & clinical development · 2024
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Ansuja Pulickal MathewDepartment of Biomedical Sciences, Chonnam National University Medical School, Gwangju, Korea.ORCID https://orcid.org/0000-0001-5025-1623
Saji UthamanDepartment of Polymer Science and Engineering, Chungnam National University, Daejeon, Korea.ORCID https://orcid.org/0000-0001-6387-7510
Eun Hui BaeDepartment of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.ORCID https://orcid.org/0000-0003-1727-2822
Jae Young LeeSchool of Materials Science and Engineering, Gwangju Institute of Science and Engineering, Gwangju, Korea.ORCID https://orcid.org/0000-0003-4493-2494
In-Kyu ParkDepartment of Biomedical Sciences, Chonnam National University Medical School, Gwangju, Korea.ORCID https://orcid.org/0000-0002-8522-8236
Chonnam National University · KRChungnam National University · KRGwangju Institute of Science and Technology · KR

Funding

Chonnam National University Hospital Biomedical Research Institute BCRI20052National Research Foundation of Korea 2020R1A2C2005620National Research Foundation of Korea 2020R1A5A2031185National Research Foundation of Korea NRF-2017M3A9E2056372National Research Foundation of Korea NRF-2019M3E5D1A02068082National Research Foundation of Korea NRF-2020M3A9G3080281
6 · The paper itself

Abstract

backgroundChronic kidney disease (CKD) is a global health problem, and there is no permanent treatment for reversing kidney failure; thus, early diagnosis and effective treatment are required. Gene therapy has outstanding potential; however, the lack of safe gene delivery vectors, a reasonable transfection rate, and kidney targeting ability limit its application. Nanoparticles can offer innovative ways to diagnose and treat kidney diseases as they facilitate targetability and therapeutic efficacy.

methodsHerein, we developed a proximal renal tubule-targeting gene delivery system based on alternative copolymer (PS) of sorbitol and polyethyleneimine (PEI), modified with vimentin-specific chitobionic acid (CA), producing PS-conjugated CA (PSC) for targeting toward vimentin-expressing cells in the kidneys. In vitro studies were used to determine cell viability, transfection efficiency, serum influence, and specific uptake in the human proximal renal tubular epithelial cell line (HK-2). Finally, the targeting efficiency of the prepared PSC gene carriers was checked in a murine model of Alport syndrome.

resultsOur results suggested that the prepared polyplex showed low cytotoxicity, enhanced transfection efficiency, specific uptake toward HK-2 cells, and excellent targeting efficiency toward the kidneys.

conclusionCollectively, from these results it can be inferred that the PSC can be further evaluated as a potential gene carrier for the kidney-targeted delivery of therapeutic genes for treating diseases.

Indexed as

AnimalsCell LineCell SurvivalDisaccharidesFluorescent DyesHumansKidneyMiceNanoparticlesPlasmidsPolyethyleneiminePolymersSugar AcidsTransfectionVimentinchitobionic acidDisaccharidesFluorescent DyesPolyethyleneiminePolymersSugar AcidsVimentinChitobionic AcidHK-2 CellsKidneyPolyethyleneimineTargeted Delivery

Identifiers

PMID34931497
PMCPMC8688343
OpenAlexW3215484357

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.